ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia

Abstract

Chemoresistant B-ALL patients are associated with increased methylation in ADAMTSL5 and CDH11. These findings need to be validated in a larger group of patients, and the functional biological and prognostic significance of differential methylation needs to be studied further.

ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma

“…Interestingly, increased ADAMTSL5 methylation was recently reported in chemotherapyresistant acute lymphoblastic leukaemia patients. [32] However, neither the genomic location of such hypermethylation nor the consequences for ADAMTSL5 expression in acute lymphoblastic leukaemia patients have been investigated. In addition, recent studies implicated ADAMTSL5 in pathologies other than cancer.…”

Putative Epigenetic Biomarkers of Stress in Red Blood Cells of Chickens Reared Across Different Biomes

“…In addition, this DMR is located downstream (≤3 kb) of the THOP1 gene ADAMTSL5 (thrombospondin type-1 domain-containing protein 6), is involved in the degradation of the extracellular matrix, has antiangiogenic properties, and plays an important role in inflammatory processes. Hypermethylation of the ADAMTSL5 gene is associated with chemoresistance to acute lymphoblastic leukemia in humans (Abdullah et al, 2017). THOP (thimet oligopeptidase 1) is important in metabolism regulation, being broadly expressed in testis (Pineau et al, 1999).…”

Differential Expression and Pathway Analysis in Drug-Resistant Triple-Negative Breast Cancer Cell Lines Using RNASeq Analysis

“…CDH11 , also known as OB Cadherin , has a role in the metastasis process and has already been established as an epigenetic biomarker of drug resistance in acute myeloid leukemia. The class of proteins to which CDH11 belongs has already been proposed as novel targets for anticancer therapy [ 20 , 21 ]. This is in the case of JQ1 treatment.…”